References
- 1
Lanas A, Garcia-Rodriguez L A, Arroyo M T. et al .
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated
with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
Am J Gastroenterol.
2007;
102
507-515
- 2
Chan F K, Wong V W, Suen B Y. et al .
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention
of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized
trial.
Lancet.
2007;
369
1621-1626
- 3
Abraham N S, El-Serag H B, Hartman C. et al .
Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk
of myocardial infarction and cerebrovascular accident.
Aliment Pharmacol Ther.
2007;
25
913-924
- 4
Take S, Mizuno M, Ishiki K. et al .
Baseline gastric mucosal atrophy is a risk factor associated with the development
of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic
ulcer diseases.
J Gastroenterol.
2007;
42
21-27
- 5
Vaira D, Zullo A, Vakil N. et al .
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication:
a randomized trial.
Ann Intern Med.
2007;
146
556-563
- 6
Chan F K, Hung L C, Suen B Y. et al .
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer
bleeding in patients with arthritis.
N Engl J Med.
2002;
347
2104-2110
- 7
Chan F K, Chung S C, Suen B Y. et al .
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med.
2001;
344
967-973
- 8
Lai K C, Chu K M, Hui W M. et al .
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer
complications.
Am J Med.
2005;
118
1271-1278
- 9
Hoer A, Gothe H, Schiffhorst G. et al .
Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs
(NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors
(PPI) on hospitalization due to peptic ulcer disease.
Pharmacoepidemiol Drug Saf.
2007;
16
854-858
- 10
Garcia-Rodriguez L A, Barreales Tolosa L.
Risk of upper gastrointestinal complications among users of traditional NSAIDs and
COXIBs in the general population.
Gastroenterology.
2007;
132
498-506
- 11
Lanas A, Garcia-Rodriguez L A, Arroyo M T. et al .
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2
inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin
and combinations.
Gut.
2006;
55
1731-1738
- 12
Bombardier C, Laine L, Reicin A. et al .
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis.
N Engl J Med.
2000;
343
1520-1528
- 13
Solomon D H, Avorn J, Sturmer T. et al .
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs:
high-risk subgroups and time course of risk.
Arthritis Rheum.
2006;
54
1378-1389
- 14
Fries S, Grosser T, Price T S. et al .
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Gastroenterology.
2006;
130
55-64
- 15
Uemura N, Okamoto S, Yamamoto S. et al .
Helicobacter pylori infection and the development of gastric cancer.
N Engl J Med.
2001;
345
784-789
- 16
Rugge M, Meggio A, Pennelli G. et al .
Gastritis staging in clinical practice: the OLGA staging system.
Gut.
2007;
56
631-636
- 17
Watabe H, Mitsushima T, Yamaji Y. et al .
Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.
Gut.
2005;
54
764-768
- 18
Kimura K, Takemoto T.
An endoscopic recognition of the atrophic border and its significance in chronic gastritis.
Endoscopy.
1969;
3
87-97
- 19
Nagahara A, Miwa H, Ogawa K. et al .
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Helicobacter.
2000;
5
88-93
- 20
Treiber G, Ammon S, Schneider E. et al .
Amoxicillin / metronidazole / omeprazole / clarithromycin: a new, short quadruple
therapy for Helicobacter pylori eradication.
Helicobacter.
1998;
3
54-58
- 21
Sugimoto M, Furuta T, Shirai N. et al .
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.
Helicobacter.
2007;
12
317-323
D. Y. Graham, MD
Michael E. DeBakey Veterans Affairs Medical Center
RM 3A-320 (111D)2002 Holcombe Boulevard
Houston
TX 77 030
USA
Fax: +1-713-790-1040
Email: dgraham@bcm.tmc.edu
